{"id":71441,"date":"2026-05-20T11:35:00","date_gmt":"2026-05-20T11:35:00","guid":{"rendered":"https:\/\/medsbase.com\/hmg-peptide\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"hmg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/hmg-peptide\/","title":{"rendered":"HMG (Human Menopausal Gonadotropin \/ Menotropin) \u2014 Pharmaceutical Grade"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is HMG (pharmaceutical-grade)?<\/h3>\n<p style=\"margin: 0;\"><strong>HMG<\/strong> (Gonadotropina Menop\u00e1usica Humana, tamb\u00e9m conhecida como <strong>menotropina<\/strong>; CAS 61489-71-2) \u00e9 uma prepara\u00e7\u00e3o glicoproteica-hormonal de origem urin\u00e1ria contendo atividade biol\u00f3gica igual de LH e FSH (75 UI LH + 75 UI FSH por frasco, a propor\u00e7\u00e3o padr\u00e3o 1:1). Purificada a partir da urina de mulheres p\u00f3s-menop\u00e1usicas \u2014 cuja produ\u00e7\u00e3o de gonadotropinas hipofis\u00e1rias est\u00e1 naturalmente elevada devido \u00e0 aus\u00eancia de inibi\u00e7\u00e3o por feedback negativo \u2014 a hMG \u00e9 o agonista <strong>dual LHCGR + FSHR<\/strong> in endocrine pharmacology and the reference tool for protocols that need simultaneous Leydig-cell \/ theca-cell steroidogenesis (LH side) and Sertoli-cell \/ granulosa-cell action (FSH side). The supplied pharmaceutical-grade material is the urinary-extracted glycoform at \u226599% HPLC purity. <em>For clinical studies use only.<\/em> Distinto das prepara\u00e7\u00f5es cl\u00ednicas de menotropina (Menopur, Menogon, Repronex).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prepara\u00e7\u00e3o glicoproteica-hormonal \u2014 mistura fixa 1:1 de atividade biol\u00f3gica de LH e FSH; agonista dual do recetor LH\/CG (LHCGR) + recetor FSH (FSHR); prepara\u00e7\u00e3o hormonal pept\u00eddica<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gonadotropina Menop\u00e1usica Humana (Menotropina; prepara\u00e7\u00e3o extra\u00edda da urina; sin\u00f3nimos: hMG, urofollitropina-com-LH, gonadotropina menop\u00e1usica)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">61489-71-2 (menotropina \/ prepara\u00e7\u00e3o mista hMG)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Componentes Ativos<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>LH<\/strong> (hormona luteinizante, heterod\u00edmero de ~30 kDa; \u03b1 92 aa + \u03b2 121 aa, glicosilada) \u2014 75 UI por frasco; <strong>FSH<\/strong> (hormona fol\u00edculo-estimulante, heterod\u00edmero de ~30 kDa; \u03b1 92 aa + \u03b2 111 aa, glicosilada) \u2014 75 UI por frasco. A subunidade \u03b1 \u00e9 partilhada entre LH, FSH, HCG e TSH; as subunidades \u03b2 conferem especificidade ao recetor. Ambas as gonadotropinas s\u00e3o extensivamente N- e O-glicosiladas.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Raz\u00e3o de Bioatividade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">LH:FSH atividade = 1:1 (a propor\u00e7\u00e3o padr\u00e3o de hMG desde a padroniza\u00e7\u00e3o da pot\u00eancia no final da d\u00e9cada de 1990; ambas as atividades medidas por bioensaio da OMS contra padr\u00f5es de refer\u00eancia internacionais)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>HCG Co-Purification (studies-relevant)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Uma caracter\u00edstica das prepara\u00e7\u00f5es de hMG derivadas da urina: an\u00e1lises de composi\u00e7\u00e3o publicadas relatam que aproximadamente <strong>95% da atividade biol\u00f3gica mediada pelo recetor de LH in vivo \u00e9 atribu\u00edvel a vest\u00edgios de HCG co-purificados da urina p\u00f3s-menopausa<\/strong> (Wolfenson et\u00a0al. 2005 and others). HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h half-life vs LH&#8217;s ~20 min \u2014 so even small HCG amounts dominate the in-vivo LH-equivalent signal. Users should be aware of this when comparing hMG to pure recombinant LH (Luveris) preparations.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanism<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Dual agonismo de GPCR. <strong>LHCGR<\/strong> (acoplado a Gs, c\u00e9lulas de Leydig \/ teca \/ granulosa \/ corpo l\u00fateo) \u2192 cascata cAMP-PKA-StAR-CYP17A1 \u2192 bioss\u00edntese de androg\u00e9nios. <strong>FSHR<\/strong> (acoplado a Gs, c\u00e9lulas de Sertoli nos homens \/ c\u00e9lulas da granulosa nas mulheres) \u2192 cascata cAMP-PKA-CYP19A1\/aromatase \u2192 suporte \u00e0 espermatog\u00e9nese (homem) ou convers\u00e3o de androg\u00e9nios em estrog\u00e9nios + matura\u00e7\u00e3o folicular (mulher). A ativa\u00e7\u00e3o dupla \u00e9 o que distingue o hMG das prepara\u00e7\u00f5es de LH puro (Luveris \/ rLH) ou FSH puro (Gonal-F \/ Puregon \/ rFSH).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prepara\u00e7\u00e3o mista \u2014 tanto a LH como a FSH s\u00e3o glicoprote\u00ednas heterodim\u00e9ricas. Subunidade \u03b1 (partilhada) ~92 aa, id\u00eantica entre LH\/FSH\/HCG\/TSH. Subunidade \u03b2 da LH ~121 aa, subunidade \u03b2 da FSH ~111 aa. Sequ\u00eancias completas dispon\u00edveis na UniProt: LH\u03b2 (P01229), FSH\u03b2 (P01225), GPH\u03b1 (P01215).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prepara\u00e7\u00e3o mista de glicoprote\u00ednas extra\u00eddas da urina \u2014 FSH (\u03b1 92aa + \u03b2 111aa) + LH (\u03b1 92aa + \u03b2 121aa) heterod\u00edmeros numa rela\u00e7\u00e3o de bioatividade de ~1:1. Sem f\u00f3rmula molecular \u00fanica devido ao padr\u00e3o heterog\u00e9neo de glicosila\u00e7\u00e3o na prepara\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Atividade da FSH: meia-vida terminal ~30\u201340 h (dependente de sialila\u00e7\u00e3o, semelhante a outras hormonas glicoproteicas). Atividade da LH em hMG: nominalmente ~10\u201320 h (mas na pr\u00e1tica determinada pela fra\u00e7\u00e3o de HCG copurificada com meia-vida de 33\u201337 h \u2014 ver nota acima sobre copurifica\u00e7\u00e3o de HCG).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder with mannitol or lactose stabilising matrix; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); ensaio biol\u00f3gico da OMS confirma atividade de LH e FSH nos 75 UI indicados. Certificado de an\u00e1lise dispon\u00edvel mediante pedido.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Reconstituir em \u00e1gua bacteriost\u00e1tica a 1,0 mL por frasco \u2192 75 UI de LH + 75 UI de FSH por mL de solu\u00e7\u00e3o de trabalho; outras dilui\u00e7\u00f5es conforme protocolo. O p\u00f3 dissolve-se rapidamente com agita\u00e7\u00e3o suave. <strong>N\u00e3o agitar; n\u00e3o vortexar<\/strong> \u2014 a mistura com elevado cisalhamento dissocia os heterod\u00edmeros \u03b1\/\u03b2 de ambos os componentes LH e FSH.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C fechado para stock de trabalho a curto prazo; \u221220 \u00b0C para armazenamento a longo prazo (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar dentro de ~30 dias. Proteger da luz. <strong>N\u00e3o congelar material reconstitu\u00eddo<\/strong> \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o dissociam os heterod\u00edmeros \u03b1\/\u03b2 da LH e FSH e destroem a bioatividade.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 HMG (Menotropina)?<\/h2>\n<p><strong>HMG<\/strong> \u2014 Gonadotropina Menop\u00e1usica Humana, tamb\u00e9m conhecida como <strong>menotropina<\/strong> (CAS 61489-71-2) \u2014 is a urinary-derived glycoprotein-hormone preparation containing equal amounts of LH (luteinising hormone) and FSH (follicle-stimulating hormone) bioactivity, standardised at 75 IU of each per vial. It is purified by ion-exchange and gel-filtration chromatography from the pooled urine of postmenopausal women, who have naturally elevated pituitary gonadotropin output (LH and FSH typically 50\u2013100+ mIU\/mL each) due to the loss of ovarian negative-feedback inhibition that accompanies menopause. The &#8220;menopausal&#8221; in the name refers to this source: postmenopausal urine is the most concentrated natural source of LH and FSH available for industrial-scale purification, and hMG has been produced from this source since the early 1960s (the original Cesare Serono-developed Pergonal preparation). The compositional refinement of hMG has evolved substantially over the decades \u2014 earlier preparations had highly variable LH:FSH ratios and significant protein-impurity loads; modern preparations (the basis of our pharmaceutical-grade material) are standardised at 75:75 IU bioactivity per vial with \u226599% HPLC purity. hMG is the canonical dual-gonadotropin pharmacological tool. Where HCG selectively activates the LHCGR, where pure-LH (recombinant Luveris) selectively activates the LHCGR at physiological half-life, where pure-FSH (recombinant Gonal-F \/ Puregon) selectively activates the FSHR, hMG activates both receptors simultaneously at a fixed 1:1 ratio. The two receptors are expressed on different cell populations within the gonad \u2014 LHCGR on Leydig cells \/ theca cells \/ luteinised granulosa \/ corpus luteum; FSHR on Sertoli cells \/ mural granulosa \u2014 so dual activation produces a complete physiological gonadotropin stimulus that more closely mimics endogenous mid-cycle pituitary output than either receptor activated alone. <strong>A studies-relevant nuance: HCG co-purification.<\/strong> Published compositional analyses of urinary-derived hMG preparations report that the bulk of the in-vivo LH-receptor bioactivity is actually attributable to trace HCG co-purified from postmenopausal urine \u2014 approximately 95% of LH-receptor-mediated bioactivity by some analyses (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life versus LH&#8217;s ~20 min, so even small HCG amounts dominate the cumulative in-vivo LH-equivalent signal. This is part of why hMG produces sustained Leydig-cell stimulation despite the nominal &#8220;LH activity&#8221; of LH itself being short-lived. For protocols where this distinction matters (pure-LH pharmacology vs HCG-contaminated mixed-LH signal), recombinant LH (Luveris) is the cleaner tool; for protocols where dual LHCGR + FSHR activation at physiological 1:1 ratio is the goal, hMG is the canonical reference. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Ativa\u00e7\u00e3o Dupla de LHCGR + FSHR<\/h2>\n<p>O mecanismo da hMG \u00e9 a soma dupla das suas duas atividades componentes, ambas bem caracterizadas na farmacologia end\u00f3crina:<\/p>\n<ul>\n<li><strong>LH (e HCG copurificada) \u2192 ativa\u00e7\u00e3o de LHCGR<\/strong> \u2014 O componente LH (e o vest\u00edgio de HCG que copurifica da urina p\u00f3s-menop\u00e1usica) liga-se ao recetor LH\/CG nas c\u00e9lulas de Leydig (test\u00edculo) e c\u00e9lulas da teca \/ granulosa \/ luteais (ov\u00e1rio). O acoplamento Gs aumenta o cAMP, ativa a PKA, regula positivamente o transporte de colesterol mediado por StAR para as mitoc\u00f4ndrias e induz as enzimas esteroidog\u00e9nicas CYP11A1 \/ CYP17A1 \/ 3\u03b2-HSD \/ 17\u03b2-HSD \u2014 impulsionando a bioss\u00edntese de novo de testosterona (masculino) ou androstenediona (feminino).<\/li>\n<li><strong>FSH \u2192 ativa\u00e7\u00e3o de FSHR<\/strong> \u2014 O componente FSH liga-se ao recetor FSH nas c\u00e9lulas de Sertoli (test\u00edculo) e c\u00e9lulas da granulosa mural (ov\u00e1rio). O FSHR tamb\u00e9m \u00e9 acoplado a Gs, mas o seu programa a jusante \u00e9 distinto: nas c\u00e9lulas de Sertoli, a ativa\u00e7\u00e3o de FSHR impulsiona a prote\u00edna de liga\u00e7\u00e3o a andr\u00f3genos (ABP), a inibina B e o programa de suporte estrutural que sustenta a espermatog\u00e9nese; nas c\u00e9lulas da granulosa, a ativa\u00e7\u00e3o de FSHR impulsiona a CYP19A1 (aromatase), convertendo andr\u00f3genos derivados das c\u00e9lulas da teca em estrog\u00e9nios, e promove a matura\u00e7\u00e3o folicular atrav\u00e9s das fases antral e pr\u00e9-ovulat\u00f3ria.<\/li>\n<li><strong>Modelo combinado de duas c\u00e9lulas e duas gonadotrofinas<\/strong> \u2014 O quadro end\u00f3crino cl\u00e1ssico. No test\u00edculo masculino, as c\u00e9lulas de Leydig estimuladas por LH produzem testosterona, que difunde para as c\u00e9lulas de Sertoli adjacentes onde a prote\u00edna de liga\u00e7\u00e3o a andr\u00f3genos induzida por FSH e a maquinaria metab\u00f3lica das c\u00e9lulas de Sertoli a convertem no microambiente de alta testosterona intratesticular que a espermatog\u00e9nese requer. No ov\u00e1rio feminino, as c\u00e9lulas da teca estimuladas por LH produzem andr\u00f3genos, que difundem para as c\u00e9lulas da granulosa adjacentes onde a aromatase induzida por FSH os converte em estrog\u00e9nios. O modelo de duas c\u00e9lulas e duas gonadotrofinas \u00e9 o quadro can\u00f3nico, e a hMG \u00e9 a ferramenta farmacol\u00f3gica can\u00f3nica para envolver ambas as metades simultaneamente.<\/li>\n<li><strong>Dessensibiliza\u00e7\u00e3o de recetores e taquifilaxia<\/strong> \u2014 Both LHCGR and FSHR undergo arrestin-mediated desensitization after sustained agonist exposure. Repeated high-dose hMG dosing can produce receptor downregulation \u2014 a well-documented phenomenon in published gonadotropin-pharmacology studies relevant to chronic-dosing protocols.<\/li>\n<li><strong>Feedback hipot\u00e1lamo-hipofis\u00e1rio<\/strong> \u2014 As with HCG, hMG-driven gonadal steroid output feeds back to the hypothalamus and pituitary to suppress endogenous GnRH and LH\/FSH secretion. In the context of HPG-suppression studies (testosterone replacement, AAS exposure, pharmacological GnRH antagonism), hMG bypasses the hypothalamic-pituitary blockade by acting directly at the gonadal receptors \u2014 preserving both Leydig-cell function (LH side) and Sertoli-cell \/ spermatogenesis-support function (FSH side) simultaneously, which is what distinguishes hMG from pure-HCG protocols in this context.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of hMG broadly mirrors that of its components: FSH activity persists with 30\u201340 h terminal half-life, LH-equivalent activity is dominated by the long-half-life co-purified HCG (33\u201337 h), and the combined preparation produces sustained 24\u201372 h dual gonadotropin stimulation per dose. Typical protocol dosing is 75\u2013225 IU SC daily in rodent or human-subject studies \u2014 equivalent to 1\u20133 vials of the 75 IU strength. <\/p>\n<h2>Published Evidence<\/h2>\n<p>hMG is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia das gonadotropinas \u2014 a refer\u00eancia can\u00f3nica de dupla ativa\u00e7\u00e3o de recetores<\/strong> \u2014 most-cited dual LHCGR + FSHR agonist in published gonadotropin studies; standard reference compound for dissecting LH-only vs FSH-only vs combined gonadotropin signalling<\/li>\n<li><strong>Spermatogenesis induction studies<\/strong> \u2014 in hypogonadotropic-hypogonadism rodent models, hMG (with or without supplementary HCG) is the canonical tool for inducing spermatogenesis by restoring both Leydig-cell testosterone production and Sertoli-cell FSH support; standard protocol cycle is 75\u2013150 IU SC three times per week for 6\u201324 months in clinical-translational studies<\/li>\n<li><strong>Female ovarian-stimulation studies<\/strong> \u2014 the historical foundation tool of in-vitro fertilisation studies; hMG drives follicular development through the antral and pre-ovulatory stages in published ovulation-induction protocols, typically combined with HCG as ovulation trigger; widely used in studies on polycystic ovary syndrome (PCOS), unexplained infertility, and assisted reproductive technologies<\/li>\n<li><strong>Two-cell two-gonadotropin model studies<\/strong> \u2014 the canonical framework of gonadal steroidogenesis pharmacology; hMG is the standard tool for activating both halves of the model simultaneously; published Sertoli-Leydig co-culture and theca-granulosa co-culture uses hMG to recapitulate the physiological dual-receptor stimulus<\/li>\n<li><strong>HPG-axis suppression-recovery<\/strong> \u2014 in published studies models where endogenous LH\/FSH has been suppressed (by exogenous testosterone, AAS exposure, or GnRH antagonism), hMG preserves both Leydig-cell function and Sertoli-cell function by direct gonadal receptor activation \u2014 distinguishing it from HCG-only protocols which preserve only LH-side function and risk Sertoli-cell atrophy<\/li>\n<li><strong>Farmacologia comparativa vs LH puro \/ FSH puro \/ HCG<\/strong> \u2014 as compara\u00e7\u00f5es publicadas frente a frente de hMG vs LH recombinante (Luveris), FSH recombinante (Gonal-F \/ Puregon), HCG recombinante (Ovidrel) e v\u00e1rias combina\u00e7\u00f5es s\u00e3o extensas; o hMG \u00e9 a refer\u00eancia mista 1:1 derivada da urina contra a qual todas estas s\u00e3o comparadas<\/li>\n<li><strong>Desenvolvimento folicular e biologia das c\u00e9lulas da granulosa<\/strong> \u2014 published ex-vivo follicular culture and primary granulosa-cell uses hMG to drive simultaneous theca-cell androgen production and granulosa-cell aromatase induction \u2014 the most physiologically relevant in-vitro stimulus available<\/li>\n<li><strong>Biologia do corpo l\u00fateo<\/strong> \u2014 sustained LHCGR activation by the LH component (and co-purified HCG) maintains corpus-luteum function and progesterone production; used in studies on the luteal phase and luteo-placental transition<\/li>\n<\/ul>\n<p>For broader context on HPG-axis and reproductive-system peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-pt\/hcg-peptide\/\">HCG (Gonadotropina Cori\u00f3nica Humana)<\/a> (agonista puro do LHCGR \u2014 compara\u00e7\u00e3o direta; atividade apenas do lado do LH), <a href=\"https:\/\/medsbase.com\/pt-pt\/kisspeptin-10\/\">Kisspeptina-10<\/a> (o agonista Kiss1R hipotal\u00e2mico a montante \u2014 impulsiona a pulsatilidade end\u00f3gena do GnRH), <a href=\"https:\/\/medsbase.com\/pt-pt\/pt-141\/\">PT-141 (Bremelanotide)<\/a> (melanocortin-receptor pharmacology \u2014 sexual-function studies), and <a href=\"https:\/\/medsbase.com\/pt-pt\/oxytocin-acetate\/\">Acetato de Oxitocina<\/a> (hormona pept\u00eddica da hip\u00f3fise posterior). Navegue pelo completo <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">peptides &amp; compounds catalog<\/a>. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks HMG (urinary-extracted menotropin) in a single lyophilized vial strength calibrated to the standard 1:1 LH:FSH bioactivity unit. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>75 UI LH + 75 UI FSH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength (the international-reference unit dose) \u2014 single-dose dual-gonadotropin stimulation, spermatogenesis-induction protocols (75\u2013225 IU SC three times per week), ovarian-stimulation studies, two-cell two-gonadotropin co-culture stimulation, comparative pharmacology vs recombinant pure-LH and pure-FSH preparations<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 75:75 IU vial is the international-reference dose unit and the format used in essentially all published gonadotropin studies and clinical practice. Multiple-vial dosing (150 IU, 225 IU per administration) is standard for higher-dose protocols. The 30-vial pack is the more economical purchase per-IU for extended-cycle or multi-cohort protocols. <\/p>\n<h2>Como Compara \u2014 HMG vs HCG<\/h2>\n<p><a href=\"https:\/\/medsbase.com\/pt-pt\/hcg-peptide\/\">HCG<\/a> e hMG s\u00e3o as duas prepara\u00e7\u00f5es de gonadotropina derivadas da urina neste cat\u00e1logo, e elas t\u00eam como alvo o sistema de recetores de gonadotropina de formas mecanicamente distintas. O HCG \u00e9 um <em>puro<\/em> agonista do recetor LH\/CG \u2014 ativa\u00e7\u00e3o apenas das c\u00e9lulas de Leydig \/ c\u00e9lulas da teca. O hMG \u00e9 a <em>dupla<\/em> LH + FSH preparation \u2014 engages both halves of the two-cell two-gonadotropin model simultaneously. The choice between them in studies depends on whether the protocol needs LH-side activation alone or combined LH-side + FSH-side activation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HMG (Menotropina)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HCG<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composi\u00e7\u00e3o<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mistura fixa 1:1: LH 75 UI + FSH 75 UI por frasco (+ vest\u00edgios de HCG que dominam o sinal equivalente ao LH in vivo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">HCG puro (extra\u00eddo da urina) \u2014 glicoprote\u00edna \u00fanica<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Recetores ativados<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR <em>e<\/em> FSHR \u2014 ativa\u00e7\u00e3o dupla do recetor de gonadotropina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apenas LHCGR \u2014 recetor \u00fanico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Fonte<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urina p\u00f3s-menopausa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urina de mulheres gr\u00e1vidas (uHCG) ou c\u00e9lulas CHO recombinantes (rHCG)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Spermatogenesis induction (preserves Sertoli-cell function), ovarian follicular stimulation, two-cell two-gonadotropin model studies, dual-receptor pharmacology<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Leydig-cell-only stimulation, ovulation triggering (LH-surge mimic), Leydig-cell-specific HPG-suppression-recovery, LHCGR pharmacology<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FSH ~30\u201340 h; atividade equivalente ao LH dominada pelo HCG copurificado (33\u201337 h)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">33\u201337 h (fase terminal)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75\u2013225 UI SC (1\u20133 frascos) por administra\u00e7\u00e3o; 3\u00d7\/semana em protocolos cr\u00f3nicos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">500\u20135.000 UI SC \/ IM (bolus \u00fanico); 250\u2013500 UI\/dia em protocolos cr\u00f3nicos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Unidade de dose em frasco<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75 IU de bioatividade (dose de refer\u00eancia internacional)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5.000 ou 10.000 IU de bioatividade<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estado WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proibido em todos os momentos em atletas masculinos (S2 \u2014 Hormonas Pept\u00eddicas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proibido em todos os momentos em atletas masculinos (S2 \u2014 Hormonas Pept\u00eddicas); isen\u00e7\u00e3o para atletas femininas<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on dual LHCGR + FSHR activation, spermatogenesis induction, or the canonical two-cell two-gonadotropin model, hMG is the standard reference compound. For studies focused on Leydig-cell-only stimulation, ovulation triggering, or HCG-specific LHCGR pharmacology, <a href=\"https:\/\/medsbase.com\/pt-pt\/hcg-peptide\/\">HCG<\/a> \u00e9 a ferramenta mais direcionada. Consulte tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-pt\/kisspeptin-10\/\">Kisspeptina-10<\/a> for upstream hypothalamic Kiss1R \/ GnRH-pulsatility studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com o nosso <a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, conservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazenar frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo, congelar frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). O bolo liofilizado \u00e9 estabilizado com manitol ou lactose e \u00e9 razoavelmente tolerante \u00e0 exposi\u00e7\u00e3o breve \u00e0 temperatura ambiente durante o manuseio, mas deve ser devolvido \u00e0 refrigera\u00e7\u00e3o prontamente. Proteger da luz. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> for each 75 IU vial, inject 1.0\u00a0mL of bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake) \u2014 this yields a working stock of 75 IU LH + 75 IU FSH per mL. For protocols that need higher concentrations (multi-vial pooling for higher single-dose), reconstitute 2\u20133 vials with the same 1.0\u00a0mL diluent total to give 150\u2013225 IU\/mL. <strong>Agitar suavemente para dissolver \u2014 n\u00e3o agitar vigorosamente, n\u00e3o usar vortex.<\/strong> A mistura de alto cisalhamento dissocia os heterod\u00edmeros \u03b1\/\u03b2 de ambos os componentes de LH e FSH e destr\u00f3i a bioatividade dos recetores de gonadotropina. O bolo de liofiliza\u00e7\u00e3o \u00e0 base de manitol normalmente dissolve-se em 30\u201360 segundos com agita\u00e7\u00e3o suave. <strong>Regras cr\u00edticas de armazenamento para material reconstitu\u00eddo:<\/strong> uma vez reconstitu\u00eddo, armazenar a 2\u20138 \u00b0C e utilizar dentro de 30 dias. <strong>N\u00e3o congelar hMG reconstitu\u00eddo<\/strong> \u2014 freeze-thaw cycles dissociate the LH and FSH \u03b1\/\u03b2 heterodimers (the same physical-chemistry constraint as HCG) and irreversibly destroy bioactivity. Protect from light. Discard if cloudiness, particulates, or marked colour change appears. For protocols requiring multiple aliquots, prepare aliquots at the time of reconstitution and store at 2\u20138 \u00b0C separately rather than freezing. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>Qual \u00e9 a diferen\u00e7a entre HMG e HCG?<\/h3>\n<p><a href=\"https:\/\/medsbase.com\/pt-pt\/hcg-peptide\/\">HCG<\/a> is a pure LH\/CG-receptor agonist \u2014 single glycoprotein hormone (CAS 9002-61-3) that binds and activates only the LHCGR on Leydig \/ theca \/ granulosa \/ luteal cells. hMG is a 1:1 mixture of LH and FSH bioactivity \u2014 distinct glycoprotein hormones (combined CAS 61489-71-2) that bind both the LHCGR (LH side) and the FSHR (FSH side). The clinical and studies consequence is that hMG produces dual-receptor stimulation that engages both halves of the two-cell two-gonadotropin model (Leydig + Sertoli in males; theca + granulosa in females), where HCG produces single-receptor stimulation of the LHCGR side only. <\/p>\n<h3>What is the HCG co-purification in hMG, and why does it matter for studies?<\/h3>\n<p>An\u00e1lises composicionais publicadas de prepara\u00e7\u00f5es de hMG derivadas da urina relatam que aproximadamente <strong>95% da bioatividade mediada pelo recetor de LH in vivo<\/strong> is actually attributable to trace HCG co-purified from postmenopausal urine, rather than to LH itself (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life vs LH&#8217;s ~20 min \u2014 so even small amounts of co-purified HCG dominate the cumulative in-vivo LH-equivalent signal. For protocols where this distinction matters (e.g., comparing pure-LH pharmacology vs HCG-contaminated mixed-LH signal), <strong>a LH recombinante (Luveris)<\/strong> \u00e9 a ferramenta mais limpa. Para protocolos onde a ativa\u00e7\u00e3o dual de LHCGR + FSHR numa propor\u00e7\u00e3o fixa de 1:1 \u00e9 o objetivo, a hMG \u00e9 a refer\u00eancia can\u00f3nica. <\/p>\n<h3>Por que \u00e9 que a hMG \u00e9 obtida da urina de mulheres p\u00f3s-menop\u00e1usicas?<\/h3>\n<p>As mulheres p\u00f3s-menop\u00e1usicas perdem a inibi\u00e7\u00e3o por feedback negativo ovariano do eixo hipot\u00e1lamo-hip\u00f3fise, o que aumenta drasticamente a produ\u00e7\u00e3o de LH e FSH pela hip\u00f3fise \u2014 os valores t\u00edpicos de LH e FSH s\u00e9ricos p\u00f3s-menop\u00e1usicos s\u00e3o de 50\u2013100+ mIU\/mL cada, uma ordem de magnitude superior aos valores pr\u00e9-menop\u00e1usicos. Ambos os horm\u00f4nios s\u00e3o ent\u00e3o eliminados pelos rins na urina de forma concentrada. A urina p\u00f3s-menop\u00e1usica coletada \u00e9, portanto, a fonte natural mais concentrada de LH + FSH para extra\u00e7\u00e3o em escala industrial. A ind\u00fastria de hMG foi constru\u00edda com base nessa percep\u00e7\u00e3o no in\u00edcio dos anos 1960 (Pergonal foi a prepara\u00e7\u00e3o original da Serono) e continua at\u00e9 hoje, embora grande parte do mercado cl\u00ednico tenha migrado para prepara\u00e7\u00f5es recombinantes de LH puro e FSH puro. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>Single-dose protocol use is typically 75\u2013225 IU SC per administration (1\u20133 vials of the 75 IU strength), with 3\u00d7\/week or daily dosing in chronic protocols. Spermatogenesis-induction protocols in published hypogonadotropic-hypogonadism studies typically use 75\u2013150 IU 3\u00d7\/week for 6\u201324 months in combination with HCG (the HCG provides additional Leydig-cell stimulation). In-vitro Sertoli-cell or granulosa-cell culture protocols typically use 1\u201310 IU\/mL in growth medium. Users should consult primary literature appropriate to the species, model, and endpoint. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre hMG e FSH recombinante puro (Gonal-F \/ Puregon)?<\/h3>\n<p>O FSH recombinante puro (follitropina alfa \/ Gonal-F; follitropina beta \/ Puregon; produzido em c\u00e9lulas CHO a partir de cDNAs clonados de FSH \u03b1 e \u03b2) cont\u00e9m <em>apenas<\/em> FSH bioactivity \u2014 no LH, no HCG. hMG contains both LH and FSH bioactivity at 1:1 ratio (plus trace HCG). For protocols that need pure FSHR activation isolated from LHCGR signalling, recombinant FSH is the correct tool. For protocols that need combined dual-receptor activation at physiological ratio, hMG is the correct tool. Published head-to-head trials in ovarian-stimulation have compared the two with broadly equivalent follicular-development endpoints but with subtly different oestradiol-response profiles (hMG tends to produce slightly higher mid-cycle oestradiol due to the LH-side androgen substrate it provides for granulosa-cell aromatase). <\/p>\n<h3>Por que o hMG reconstitu\u00eddo n\u00e3o pode ser congelado?<\/h3>\n<p>A mesma raz\u00e3o que o HCG \u2014 tanto o LH quanto o FSH s\u00e3o heterod\u00edmeros de duas subunidades n\u00e3o covalentemente associadas (\u03b1 + \u03b2 cada). A intera\u00e7\u00e3o \u03b1\/\u03b2 \u00e9 est\u00e1vel no liofilizado (sem \u00e1gua para perturbar a intera\u00e7\u00e3o) e est\u00e1vel em solu\u00e7\u00e3o aquosa refrigerada a 2\u20138 \u00b0C (a cin\u00e9tica de dissocia\u00e7\u00e3o \u00e9 lenta em baixa temperatura). Mas a forma\u00e7\u00e3o de cristais de gelo durante o congelamento separa fisicamente as subunidades, e elas se reassociam de forma ineficiente ap\u00f3s o descongelamento. O resultado \u00e9 que o hMG congelado e descongelado ret\u00e9m uma grande fra\u00e7\u00e3o de imunorreatividade, mas perde uma grande fra\u00e7\u00e3o de atividade biol\u00f3gica. O hMG liofilizado pode ser congelado e \u00e9 est\u00e1vel a \u221220 \u00b0C; o hMG reconstitu\u00eddo n\u00e3o pode. <\/p>\n<h3>Qual \u00e9 o status regulat\u00f3rio da WADA para o hMG?<\/h3>\n<p>hMG \/ menotropin is on the World Anti-Doping Agency (WADA) Prohibited List under class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times \u2014 both in-competition and out-of-competition \u2014 for male athletes. Users conducting human-subject studies with hMG need to be aware of this regulatory status. For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>How does this pharmaceutical-grade hMG compare with the branded clinical preparations (Menopur, Menogon, Repronex)?<\/h3>\n<p>The branded clinical preparations are urinary-extracted menotropin (Menopur, Menogon, Repronex; the historical Pergonal preparation has been largely discontinued) packaged under various manufacturer SKUs for clinical use in assisted reproductive technologies. The pharmaceutical-grade hMG supplied here is the same urinary-extracted preparation at \u226599% HPLC purity, supplied without a clinical-use label and intended for clinical studies only. Users seeking clinical-use menotropin should obtain it through a clinical supply chain; users seeking pharmaceutical-grade material for in-vitro receptor pharmacology, rodent in-vivo work, or other clinical applications can use the material supplied here. <\/p>\n<h3>Can hMG be combined with HCG, Kisspeptin-10, or testosterone in protocols?<\/h3>\n<p>Yes \u2014 these compounds target different layers of the HPG axis and are commonly combined in published studies. The most-published combinations are hMG + HCG (the standard clinical and protocol for spermatogenesis induction in hypogonadotropic-hypogonadism models \u2014 hMG provides FSH-side support, additional HCG provides supplemental LH-side stimulation); hMG + <a href=\"https:\/\/medsbase.com\/pt-pt\/kisspeptin-10\/\">Kisspeptina-10<\/a> (upstream + downstream dissection \u2014 kisspeptin drives endogenous GnRH while hMG provides direct gonadal stimulation); hMG + exogenous testosterone (for HPG-suppression-recovery, where the testosterone suppresses endogenous LH\/FSH and hMG bypasses the suppression by acting directly at the gonad). Reconstitute each separately and follow each compound&#8217;s specific storage rules \u2014 neither hMG nor HCG should be frozen reconstituted. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HPG-Axis and Reproductive Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/hcg-peptide\/\"><strong>HCG (Gonadotropina Cori\u00f3nica Humana)<\/strong><\/a> \u2014 Agonista puro do recetor LH\/CG \u2014 compara\u00e7\u00e3o direta; atividade apenas no lado LH<\/li>\n<li><a href=\"\/pt-pt\/kisspeptin-10\/\"><strong>Kisspeptina-10<\/strong><\/a> \u2014 Agonista hipotal\u00e2mico Kiss1R \u2014 regulador do eixo HPG a montante, impulsiona a pulsatileidade do GnRH<\/li>\n<li><a href=\"\/pt-pt\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Melanocortin-4 receptor agonist \u2014 sexual-function studies<\/li>\n<li><a href=\"\/pt-pt\/oxytocin-acetate\/\"><strong>Acetato de Oxitocina<\/strong><\/a> \u2014 Posterior pituitary nonapeptide \u2014 reproductive and social bonding<\/li>\n<li><a href=\"\/pt-pt\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 An\u00e1logo do GHRH \u2014 eixo end\u00f3crino diferente, frequentemente coestudado<\/li>\n<li><a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, conservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Prepara\u00e7\u00e3o dupla de glicoprote\u00ednas LH + FSH \u2014 propor\u00e7\u00e3o de bioatividade 1:1 (75 UI cada)<br \/>\n\u2705 Agonista duplo dos recetores de gonadotropina LHCGR + FSHR<br \/>\n\u2705 Menotropina extra\u00edda da urina de mulheres p\u00f3s-menop\u00e1usicas (CAS 61489-71-2)<br \/>\n\u2705 Modelo de duas c\u00e9lulas e duas gonadotropinas \u2014 ativa as c\u00e9lulas de Leydig+Sertoli ou teca+granulosa<br \/>\n\u2705 Standard tool for spermatogenesis-induction &amp; ovarian-stimulation studies<\/p>\n<p><strong>HMG (Pharmaceutical Grade)<\/strong> cont\u00e9m Menotropina Humana extra\u00edda da urina (menotropina).<\/p>","protected":false},"featured_media":71453,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6490,6495,6492,6497,6498,6496,6493,6494],"class_list":["post-71441","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gonadotropin","product_tag-hmg","product_tag-hpg-axis","product_tag-human-menopausal-gonadotropin","product_tag-lhcgr-fshr-agonist","product_tag-menotropin","product_tag-reproductive-research","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/71441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=71441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/71453"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=71441"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=71441"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=71441"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=71441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}